Takeda to Discontinue GAMMAGARD S/D by End of 2027, Inventory to Deplete Through 2028
Takeda Pharmaceutical announced plans to discontinue GAMMAGARD S/D production by December 31, 2027, with remaining inventory available until depleted or expired. The immunoglobulin therapy phase-out signals a portfolio shift as the Japanese pharma giant realigns its product offerings in the competitive immune deficiency treatment market.
ViaNews Editorial Team (Markets)•